| 06/03/2010 |
Tioga Pharmaceuticals, Inc. announced
today that the company has dosed its first subject in a
Phase 3 clinical trial to evaluate asimadoline for the
treatment of patients with diarrhea-predominant irritable
bowel syndrome (D-IBS). .
read more... |
| 04/05/2010 |
Tioga Pharmaceuticals, Inc. announced
today that the company has reached agreement with the U.S.
Food and Drug Administration (FDA) on Special Protocol
Assessments (SPAs) for the Phase 3 efficacy protocols for
its product candidate, asimadoline, for the treatment of
patients with diarrhea-predominant irritable bowel syndrome
(D-IBS).
read more... |
| 02/17/2010 |
Tioga Pharmaceuticals, Inc. Raises $18
Million to Fund Phase 3 Clinical Trial in Irritable Bowel
Syndrome.
read more... |
| 09/01/2009 |
Tioga Pharmaceuticals, Inc. and
Ono Pharmaceutical Co, Ltd. Osaka, Japan today
announced an exclusive license agreement under which Ono has
licensed rights to develop and commercialize
asimadoline in Japan, South Korea and Taiwan.
Tioga retains all other rights to asimadoline.
read more... |
05/20/2008
|
Tioga Pharmaceuticals, Inc. today announced that its oral kappa opioid receptor agonist, asimadoline, has demonstrated statistically significant results in treating Irritable Bowel Syndrome (IBS) patients in a recently completed 596 subject phase 2b randomized, double blind, placebo-controlled, dose ranging, clinical trial.
read more...
|
| 01/09/2006 |
Tioga's Series A Round: $24M For Phase IIb Trial Of IBS Drug more... |
| 07/06/2005 |
Tioga Pharmaceuticals, Inc. Formed To Develop Merck KGaA’s asimadoline more... |
